Hologic, Inc.

Hologic, Inc.

HOLX

Market Cap$18.12B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Hologic, Inc.Hologic, Inc.38.90%-4.9-

Earnings Call Q2 2023

May 1, 2023 - AI Summary

Hologic reported strong financial results for the second quarter of fiscal 2023, with total revenue of $1.03 billion and non-GAAP earnings per share of $1.06, both exceeding expectations.
The company's organic revenue, excluding COVID, grew 21.9%, driven by strong performance in Diagnostics (14.9% growth), Surgical (25.2% growth), and Breast Health (25.7% growth).
Hologic reaffirmed its guidance for low double-digit organic revenue growth for each division in fiscal 2023, excluding COVID. However, they acknowledged that tougher comps in the third quarter may impact future growth rates.

Exclusive for Stockcircle Pro members

Sign upSign Up
$68.00

Target Price by Analysts

12.9% downsideHologic Target Price DetailsTarget Price
$109.56

Current Fair Value

40.3% upside

Undervalued by 40.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$18.12 Billion
Enterprise Value-
Dividend Yield$0.0 (0.0%)
Earnings per Share$1.92
Beta0.48
Outstanding Shares233,376,948
Avg 30 Day Volume1,541,689

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio38.85
PEG-174.67
Price to Sales4.88
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Hologic, Inc.

6,478 employees
CEO: Stephen MacMillan

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.